Understanding Immunotherapy for NSCLC with PD-1 and PD-L1 Biomarkers

Learn more about lung cancer at www.YouAndLungC...
This animation provides an overview of immunotherapy for non-small cell lung cancer (NSCLC) with PD-1 and PD-L1 biomarkers. The option of immunotherapy is one more reason why everyone diagnosed with NSCLC should have biomarker testing. Watch to learn about PD-1, PD-L1, and CTLA-4 checkpoint proteins, and the different immune checkpoint inhibitor drugs that act on PD-1, PD-L1, and CTLA-4. You can also learn about finding a clinical trial if you have PD-1, PD-L1, or CTLA-4.